Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary

On March 3, 2023, Insmed announced the granting of inducement awards to 17 new employees as part of its hiring strategy. These awards, compliant with NASDAQ Listing Rule 5635(c)(4), involve options to purchase a total of 136,800 shares of Insmed common stock at an exercise price of $20.24 per share, the closing price on March 1, 2023. The options come with a 10-year term and a four-year vesting schedule, incentivizing employee retention and performance. Insmed focuses on transforming lives through therapies for serious and rare diseases.

Positive

• Inducement awards granted to 17 new employees to attract talent.
• Options to purchase 136,800 shares at an exercise price of $20.24, encouraging employee investment in the company.

Negative

• None.

BRIDGEWATER, N.J., March 3, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 17 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.

In connection with the commencement of their employment, the employees received options on March 1, 2023 to purchase an aggregate 136,800 shares of Insmed common stock at an exercise price of $20.24 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.

The options have a 10-year term and a four-year vesting schedule, with 25% of the shares subject to the option vesting on the first anniversary of the relevant grant date and 12.5% of the shares subject to the option vesting every six months thereafter through the fourth anniversary of the relevant grant date, subject to the relevant employee's continued service with Insmed on the applicable vesting date.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a footprint across Europe and in Japan. For more information, visit www.insmed.com.

Contact:

Investors:

Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com 

Media:

Mandy Fahey
Executive Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301761233.html

SOURCE Insmed Incorporated

FAQ

What are the details of Insmed's inducement awards announced on March 3, 2023?

Insmed's inducement awards granted to 17 new employees include options to purchase 136,800 shares at $20.24 per share, with a 10-year term and a four-year vesting schedule.

How many shares were included in the inducement awards by Insmed?

The inducement awards by Insmed included options to purchase a total of 136,800 shares of common stock.

What was the exercise price for Insmed's inducement awards?

The exercise price for the inducement awards granted was $20.24 per share.

What is the vesting schedule for the options granted by Insmed?

The options granted have a four-year vesting schedule, with 25% vesting on the first anniversary of the grant date and 12.5% vesting every six months thereafter.